New York Magazine examines cancer drug pricing

New York Magazine examines cancer drug pricing
New York Magazine examines cancer drug pricing

In a story published online on October 20th, New York magazine took readers through the Memorial Sloan-Kettering/Zaltrap pricing battle with Leonard Saltz, one of the three oncologists who penned the op-ed in the New York Times which started it all and concluded with Sanofi/Regeneron slashing the price of then new breast cancer drug Zaltrap in half due to "market resistance."

The seven-page article online also quoted Hagop Kantarjian, head of the Department of Leukemia at the University of Texas's MD Anderson Cancer Center, who is currently campaigning against Gleevec, a leukemia treatment whose price has tripled since 2001.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.